Pathophysiology and Treatment of Enteric Hyperoxaluria.

Celeste Witting, Craig B Langman, Dean Assimos, Michelle A Baum, Annamaria Kausz, Dawn Milliner, Greg Tasian, Elaine Worcester, Meaghan Allain, Melissa West, Felix Knauf, John C Lieske

Journal: Clinical journal of the American Society of Nephrology : CJASN 2022;16(3):487-495

PMID: 32900691

Abstract

Enteric hyperoxaluria is a distinct entity that can occur as a result of a diverse set of gastrointestinal disorders that promote fat malabsorption. This, in turn, leads to excess absorption of dietary oxalate and increased urinary oxalate excretion. Hyperoxaluria increases the risk of kidney stones and, in more severe cases, CKD and even kidney failure. The prevalence of enteric hyperoxaluria has increased over recent decades, largely because of the increased use of malabsorptive bariatric surgical procedures for medically complicated obesity. This systematic review of enteric hyperoxaluria was completed as part of a Kidney Health Initiative-sponsored project to describe enteric hyperoxaluria pathophysiology, causes, outcomes, and therapies. Current therapeutic options are limited to correcting the underlying gastrointestinal disorder, intensive dietary modifications, and use of calcium salts to bind oxalate in the gut. Evidence for the effect of these treatments on clinically significant outcomes, including kidney stone events or CKD, is currently lacking. Thus, further research is needed to better define the precise factors that influence risk of adverse outcomes, the long-term efficacy of available treatment strategies, and to develop new therapeutic approaches.

Copyright © 2021 by the American Society of Nephrology.

Address: Feinberg School of Medicine, Northwestern University, Chicago, Illinois.; Division of Kidney Diseases, Lurie Children's Hospital of Chicago, Chicago, Illinois.; Department of Urology, University of Alabama-Birmingham, Birmingham, Alabama.; Division of Nephrology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.; Allena Pharmaceuticals, Inc., Newton, Massachusetts.; Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.; Department of Surgery, Division of Urology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.; Department of Medicine, University of Chicago, Chicago, Illinois.; American Society of Nephrology, Washington, DC.; Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.